Screening and Surveillance for Barrett Esophagus

Paul Lochhead, Andrew T Chan

Research output: Contribution to journalComment/debate

5 Citations (Scopus)

Abstract

When Norman Barrett described columnar metaplasia in the esophagus in 1950, he could not have predicted the controversies that would arise from the condition that now bears his name. In response to chronic injury from reflux esophagitis, the normally squamous-lined lower esophagus becomes reepithelialized with intestinal-type (mucus-secreting) columnar epithelium, giving rise to Barrett esophagus. In a minority of cases, this metaplastic epithelium develops dysplasia, which, in turn, can progress to esophageal adenocarcinoma, a malignant neoplasm associated with substantial morbidity and a 5-year survival rate of less than 20%. Over the past 40 years, the incidence of esophageal adenocarcinoma has risen markedly in the United States, from 0.4 cases per 100 000 in 1975 to 2.6 cases per 100 000 in 2009.1 Barrett esophagus and esophageal adenocarcinoma share similar epidemiologic risk factors, including gastroesophageal reflux disease (GERD), white race, male sex, increasing age, tobacco use, and central adiposity.
Original languageEnglish
Pages (from-to)159-160
Number of pages2
JournalJAMA Internal Medicine
Volume175
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Barrett Esophagus
Adenocarcinoma
Esophagus
Epithelium
Epidemiologic Factors
Peptic Esophagitis
Adiposity
Metaplasia
Tobacco Use
Mucus
Gastroesophageal Reflux
Names
Survival Rate
Morbidity
Incidence
Wounds and Injuries
Neoplasms

Keywords

  • Barrett Esophagus
  • Screening
  • Surveillance

Cite this

Screening and Surveillance for Barrett Esophagus. / Lochhead, Paul; Chan, Andrew T.

In: JAMA Internal Medicine, Vol. 175, No. 2, 2015, p. 159-160.

Research output: Contribution to journalComment/debate

Lochhead, Paul ; Chan, Andrew T. / Screening and Surveillance for Barrett Esophagus. In: JAMA Internal Medicine. 2015 ; Vol. 175, No. 2. pp. 159-160.
@article{4dd58516d1bf4c2698712c9ee87d98cf,
title = "Screening and Surveillance for Barrett Esophagus",
abstract = "When Norman Barrett described columnar metaplasia in the esophagus in 1950, he could not have predicted the controversies that would arise from the condition that now bears his name. In response to chronic injury from reflux esophagitis, the normally squamous-lined lower esophagus becomes reepithelialized with intestinal-type (mucus-secreting) columnar epithelium, giving rise to Barrett esophagus. In a minority of cases, this metaplastic epithelium develops dysplasia, which, in turn, can progress to esophageal adenocarcinoma, a malignant neoplasm associated with substantial morbidity and a 5-year survival rate of less than 20{\%}. Over the past 40 years, the incidence of esophageal adenocarcinoma has risen markedly in the United States, from 0.4 cases per 100 000 in 1975 to 2.6 cases per 100 000 in 2009.1 Barrett esophagus and esophageal adenocarcinoma share similar epidemiologic risk factors, including gastroesophageal reflux disease (GERD), white race, male sex, increasing age, tobacco use, and central adiposity.",
keywords = "Barrett Esophagus, Screening, Surveillance",
author = "Paul Lochhead and Chan, {Andrew T}",
year = "2015",
doi = "10.1001/jamainternmed.2014.6983",
language = "English",
volume = "175",
pages = "159--160",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Screening and Surveillance for Barrett Esophagus

AU - Lochhead, Paul

AU - Chan, Andrew T

PY - 2015

Y1 - 2015

N2 - When Norman Barrett described columnar metaplasia in the esophagus in 1950, he could not have predicted the controversies that would arise from the condition that now bears his name. In response to chronic injury from reflux esophagitis, the normally squamous-lined lower esophagus becomes reepithelialized with intestinal-type (mucus-secreting) columnar epithelium, giving rise to Barrett esophagus. In a minority of cases, this metaplastic epithelium develops dysplasia, which, in turn, can progress to esophageal adenocarcinoma, a malignant neoplasm associated with substantial morbidity and a 5-year survival rate of less than 20%. Over the past 40 years, the incidence of esophageal adenocarcinoma has risen markedly in the United States, from 0.4 cases per 100 000 in 1975 to 2.6 cases per 100 000 in 2009.1 Barrett esophagus and esophageal adenocarcinoma share similar epidemiologic risk factors, including gastroesophageal reflux disease (GERD), white race, male sex, increasing age, tobacco use, and central adiposity.

AB - When Norman Barrett described columnar metaplasia in the esophagus in 1950, he could not have predicted the controversies that would arise from the condition that now bears his name. In response to chronic injury from reflux esophagitis, the normally squamous-lined lower esophagus becomes reepithelialized with intestinal-type (mucus-secreting) columnar epithelium, giving rise to Barrett esophagus. In a minority of cases, this metaplastic epithelium develops dysplasia, which, in turn, can progress to esophageal adenocarcinoma, a malignant neoplasm associated with substantial morbidity and a 5-year survival rate of less than 20%. Over the past 40 years, the incidence of esophageal adenocarcinoma has risen markedly in the United States, from 0.4 cases per 100 000 in 1975 to 2.6 cases per 100 000 in 2009.1 Barrett esophagus and esophageal adenocarcinoma share similar epidemiologic risk factors, including gastroesophageal reflux disease (GERD), white race, male sex, increasing age, tobacco use, and central adiposity.

KW - Barrett Esophagus

KW - Screening

KW - Surveillance

U2 - 10.1001/jamainternmed.2014.6983

DO - 10.1001/jamainternmed.2014.6983

M3 - Comment/debate

VL - 175

SP - 159

EP - 160

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -